ResMed (ASX:RMD) share price on watch after Q2 update disappoints

ResMed shares will be in focus today after its Q2 results fell short of expectations.

| More on:
A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today

Image source: Getty Images

Key points

  • ResMed delivered solid revenue and profit growth in the second quarter
  • A major competitor product recall boosted demand
  • However, its revenue still fell short of analyst expectations

The ResMed Inc. (ASX: RMD) share price will be one to watch on Friday morning.

This follows the release of the sleep treatment focused medical device company’s second quarter update.

ResMed share price on watch after falling short of expectations

  • Revenue increased 12% (13% in constant currency) to US$894.9 million
  • Gross margin contracted by 230 basis points to 57.6%
  • Net income up 12% to US$201.8 million
  • Diluted earnings per share up 11% to US$1.37
  • Quarterly dividend of 42 US cents declared

What happened during the quarter?

For the three months ended 31 December, ResMed reported a 12% increase in revenue to US$894.9 million. This was driven by increased demand for sleep and respiratory care devices and the benefits of a major product recall by one of its largest competitors.

ResMed recorded top line growth across all its operations. Revenue in the Americas grew 14%, in Europe, Asia, and other markets it grew 12%, and its software-as-a-service business reported 8% revenue growth.

However, while this revenue growth was strong, it still fell short of the market’s expectations. The consensus estimate was for revenue of US$927.5 million. In after hours trade in the US, the ResMed share price is down 4.5% on the news.

Also potentially weighing on the ResMed share price today was its softer gross margin. Management advised that its gross margin decreased by 230 basis points due to higher freight and manufacturing costs, which were partially offset by favourable product mix changes.

Management commentary

ResMed’s CEO, Mick Farrell, was pleased with the company’s performance during the quarter, especially given the supply chain challenges it was facing.

He said: “Our second-quarter results reflect continued strong performance across our business resulting in double-digit top-line revenue growth, driven by ongoing high demand for our sleep and respiratory care products, and solid growth in our software-as-a-service business. Our global ResMed team continues to find ways to deliver products and solutions to our customers, even amid ongoing supply chain challenges that have limited additional access to critical electronic components.”

“We are working every day to meet the extraordinary demand generated by our competitor’s ongoing device recall. We continue to ensure priority for the highest-need patients first, and we are working with physicians, providers, and healthcare systems to maintain delivery of medical devices and digital health solutions for the patients who need care,” he added.

Mr Farrell remains positive on the future and notes that the company continues to focus on improving 250 million lives by 2025.

He commented: “Despite constantly evolving market dynamics, we remain focused on our goal to improve 250 million lives in the year 2025; supporting patients with the sleep apnea therapy, respiratory care therapy, and digital health solutions they need as we deliver value for all of our customers.”

“We are investing in medical device research and development, as well as digital health innovation that will unlock value across the healthcare system. I am incredibly proud of our global ResMed team, working around the clock with providers and physicians across 140 countries to get products directly into the hands of patients who most need our help,” Mr Farrell concluded.

Should you invest $1,000 in ResMed right now?

Before you consider ResMed, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and ResMed wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Team celebrating corporate success screaming with joy.
Earnings Results

OFX share price soars 8% on record FY22 results

A huge year for the company sees investors rallying behind its stock today.

Read more »

Sad Probuild construction worker in front of half built house puts his hand to his forehead as he talks on the phone
Earnings Results

James Hardie share price stumbles despite 36% lift in annual sales

Both quarterly and yearly net income figures increased markedly.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

Two laughing young women holding shopping bags ride an escalator up to another level in a Scentre Group shopping centre
Earnings Results

Scentre share price defies ASX 200 sell-off to lift on strong earnings outlook

The retail property group owns and operates Westfield properties across Australia and New Zealand.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Bank Shares

CBA share price pushes higher on consensus-beating quarterly update

CBA's Q3 update has smashed expectations. Here's by how much...

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Earnings Results

Orica share price spikes amid 25% jump in sales revenue

The company posted mixed results today.

Read more »

Man ponders a receipt as he looks at his laptop.
Earnings Results

Xero share price in focus amid strong FY22 revenue growth but full-year loss

Xero has released its full-year results...

Read more »

CBA share price represented by branch welcome sign
Bank Shares

CBA share price on watch following $2.4bn Q3 cash profit

CBA has released its Q3 results this morning. How did it perform?

Read more »